艾滋病已经成为全球性疾病，多种药物用于艾滋病治疗，但疗效和毒性反应的个体差异严重影响抗艾滋病药物的疗效。研究表明，遗传多态性是导致药物反应个体差异的主要因素。近年来，国内外学者对抗艾滋病药物进行基因组学研究发现，基因多态性很大程度上决定了这类药物反应的个体差异。该文针对国内常用的4类艾滋病治疗药物，即核苷类逆转录酶抑制剂（NRTIs ）、非核苷类逆转录酶抑制剂（NNRTIs）、蛋白酶抑制剂（PIs）和整合酶抑制剂（raltegravir），对抗逆转录病毒药物及其基因组学研究进展进行综述。%AIDS has become a global disease,and a variety of drugs are used in the treatment of AIDS ,but the interindividual variabilities in efficacy and toxicity remain important limitations for the use of these drugs.Studies have shown genetic polymor-phism is the main reason for interindividual variabilities of drug reaction.In recent years,scholars focused on the pharmacog-enomics of anti-AIDS drugs and found that genetic polymor-phisms,in large part,determine the interindividual variabilities of the responese of these drugs.This paper reviews the research progress on pharmacogenomics of the four types of anti-AIDS drugs commonly used in China,including nucleoside reverse transcriptase inhibitors (NRTIs),non-nucleoside reverse tran-scriptase inhibitors (NNRTIs),protease inhibitors (PIs)and integrase inhibitors (raltegravir).
展开▼
